ABSTRACT
Purpose
The present investigation aimed at brain targeting of sumatriptan succinate (SS) for its optimal therapeutic effect in migraine through nanoparticulate drug delivery system using poly (butyl cyanoacrylate) (PBCA) and bovine serum albumin linked with apolipoprotein E3 (BSA-ApoE).
Method
The study involved formulation optimization of PBCA nanoparticles (NPs) using central composite design for achieving minimum particle size, maximum entrapment efficiency along with sustained drug release. SS incorporated in BSA-ApoE NPs (S-AA-NP) were prepared by desolvation technique and compared with SS loaded polysorbate 80 coated optimized PBCA NPs (FPopt) in terms of their brain uptake potential, upon oral administration in male Wistar rats. The NPs were characterized by FTIR, thermal, powder XRD and TEM analysis.
Results
The in vivo studies of FPopt and S-AA-NP on male Wistar rats demonstrated a fairly high brain/plasma drug ratio of 9.45 and 12.67 respectively 2 h post oral drug administration. The behavioural studies on male Swiss albino mice affirmed the enhanced anti-migraine potential of S-AA-NP than FPopt (P < 0.001).
Conclusion
The results of this work, therefore, indicate that BSA-ApoE NPs are significantly better than polysorbate 80 coated PBCA NPs for brain targeting of SS (P < 0.05) and also offer an improved therapeutic strategy for migraine management.
Similar content being viewed by others
Abbreviations
- AA-NP:
-
Dummy Apolipoprotein E coupled bovine serum albumin nanoparticles (without drug)
- ApoE:
-
Apolipoprotein E
- BBB:
-
Blood Brain Barrier
- BSA:
-
Bovine Serum Albumin
- BSA-ApoE:
-
Bovine Serum Albumin covalently linked with Apolipoprotein E
- DSC:
-
Differential Scanning Calorimetry
- FCopt :
-
Sumatriptan succinate loaded polysorbate 80 coated chitosan solid lipid nanoparticles
- FPopt :
-
Sumatriptan succinate loaded polysorbate 80 coated optimized Poly (butyl cyanoacrylate) nanoparticles
- FTIR:
-
Fourier-Transform Infrared Spectroscopy
- HPLC:
-
High-Performance Liquid Chromatography
- mmol:
-
Millimoles
- nBCA:
-
n-Butyl-2-cyanoacrylate
- NPs:
-
Nanoparticles
- PBCA:
-
Poly (butyl cyanoacrylate) (PBCA)
- pXRD:
-
Powder X-Ray Diffraction
- S-AA-NP:
-
Sumatriptan succinate loaded apolipoprotein E coupled BSA nanoparticles
- SLN:
-
Solid lipid nanoparticles
- SS:
-
Sumatriptan Succinate
- TEM:
-
Transmission Electron Microscopy
- TGA:
-
Thermogravimetric analysis
REFERENCES
Lipton RB, Silberstein SD, Stewart WF. An update on the epidemiology of migraine. Headache. 1994;34:319–28.
Shapiro RE, Goadsby PJ. The long drought: the dearth of public funding for headache research. Cephalalgia. 2007;27:991–4.
Girotra P, Singh SK, Saini D. Disentangling the intricacies of migraine: a review. CNS Neurol Disord Drug Targets. 2014;13:776–91.
Ferrari MD, Saxena PR. Clinical effects and mechanism of action of sumatriptan in migraine. Clin Neurol Neurosurg. 1992;94:73–7.
Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache. 1994;34:394–9.
Edvinsson L, Tfelt-Hansen P. The blood brain barrier in migraine treatment. Cephalalgia. 2008;24:1245–58.
Nagpal K, Singh SK, Mishra DN. Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB. Expert Opin Drug Deliv. 2013;10:927–55.
Alonso MJ, Csaba NS. Nanostructured biomaterials for overcoming biological barriers. RSC Publishing; 2012.
Gao S, Xu Y, Asghar S, Chen M, Zou L, Eltayeb S, et al. Poly butylcyanoacrylate nanocarriers as promising targeted drug delivery systems. J Drug Target. 2015;4:1–16.
Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: reparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm. 2010;76:189–99.
Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv Drug Deliv Rev. 2014;71:2–14.
Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001;47:65–81.
Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood–brain barrier. J Drug Target. 2002;10:317–25.
Ramge P, Unger RE, Oltrogge JB, Zenker D, Begley D, Kreuter J, et al. Polysorbate 80-coating enhances uptake of polybutylcyano-acrylate (PBCA)- nanoparticles by human, bovine and murine primary brain capillary endothelial cells. Eur J Neurosci. 2000;12:1931–40.
Alyautdin R, Gothier D, Petrov V, Kharkevich D, Kreuter J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly (butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm. 1995;41:44–8.
Yu Z, Yu M, Zhang Z, Hong G, Xiong Q. Bovine serum albumin nanoparticles as controlled release carrier for local drug delivery to the inner ear. Nanoscale Res Lett. 2014;9:1–7.
Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, et al. Covalent linkage of Apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther. 2006;317:1246–53.
Hoffmann M, Scharnagl H, Panagiotou E, Banghard W, Wieland H, Marz W. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. J Am Soc Nephrol. 2001;12:524–30.
Ribalta J, Vallve JC, Girona J, Masana L. Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. Curr Opin Clin Nutr Metab Care. 2003;6:177–87.
Wu LS. Product testing with consumers for research guidance. ASTM Int. 1989;1035:48–50.
Nagpal K, Singh SK, Mishra DN. Minocycline encapsulated chitosan nanoparticles for central antinociceptive activity. Int J Biol Macromol. 2015;72:131–5.
Girotra PH, Singh SK, Kumar P. Sumatriptan succinate loaded chitosan solid lipid nanoparticles for enhanced anti-migraine potential. Int J Biol Macromol. 2015;81:467–76.
Weber C, Kreuter J, Langer K. Desolvation process and surface characteristics of HSA-nanoparticles. Int J Pharm. 2000;196:197–200.
Langer K, Balthasar S, Vogel V, Dinauer N, Von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm. 2003;257:169–80.
Yu Z, Kastenmuller G, He Y, Belcredi P, Moller G, Prehn C, et al. Differences between human plasma and serum metabolite profiles. PLoS One. 2011;6:e21230.
Girotra PH, Singh SK, Kumar G. Reversed phase HPLC method development and validation for the quantification of sumatriptan succinate nanoparticles in rat plasma and brain homogenate. Inventi Impact: Biomed Anal. 2016;1:1–5.
Girotra P, Singh SK, Kumar G. Development of Zolmitriptan loaded PLGA/poloxamer nanoparticles using quality by design approach for migraine management. Int J Biol Macromol. 2016;85:92–101.
Patila S, Sandberg A, Heckert E, Self W, Sea S. Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials. 2007;28:4600–7.
Ritger PL, Peppas NA. A simple equation for description of solute release II: Fickian and anomalous release from swellable devices. J Control Release. 1987;5:37–42.
Nagpal K, Singh SK, Mishra DN. Formulation, optimization, in vivo pharmacokinetic behavioural and biochemical estimations of minocycline loaded chitosan nanoparticles for enhanced brain uptake. Chem Pharm Bull. 2013;61:258–72.
Alam S, Khan ZI, Mustafa G, Kumar M, Islam F, Bhatnagar A, et al. Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study. Int J Nanomedicine. 2012;7:5705–18.
Culot M, Fabulas-da Costa A, Sevin E, Szorath E, Martinsson S, Renftel M, et al. A simple method for assessing free brain/free plasma ratios using an in vitro model of the blood brain barrier. PLoS ONE. 2013;8:e80634.
Nikai T, Basbaum AI, Ahn AH. Profound reduction of somatic and visceral pain in mice by intrathecal administration of the anti-migraine drug, sumatriptan. Pain. 2008;139:533–40.
Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT (1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol. 2004;56:371–81.
Digre KB, Brennan KC. Shedding light on photophobia. J Neuroophthalmol. 2012;32:68–81.
Okamoto K, Thompson R, Tashiro A, Chang Z, Bereiter DA. Bright light produces Fos-positive neurons in caudal trigeminal brainstem. Neuroscience. 2009;160:858–64.
Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood–brain barrier disruption. Br J Pharmacol. 1993;109:788–92.
Vijayan L, Bansal D, Ray SB. Nimodipine down-regulates CGRP expression in the rat trigeminal nucleus caudalis. Indian J Exp Biol. 2012;50:320–4.
ACKNOWLEDGMENTS AND DISCLOSURES
The authors acknowledge the Coordinator, DST FIST, Department of Pharmaceutical Sciences (GJU S&T, Hisar) and SAIF, Panjab University (Chandigarh) for providing particle size analysis and TEM analysis facility respectively. The authors are thankful to Department of Science & Technology, New Delhi for providing DST-INSPIRE fellowship as financial assistance. The contribution of Dr. Tikva Vogel in providing the gift sample of ApoE is gratefully acknowledged. The authors also wish to thank Dr. A.K. Mohanty, (Animal Biotechnology Centre, National Dairy Research Institute, Karnal, India) for kindly helping in the thiolation of apolipoprotein E. The authors report no conflict of interest and are solely responsible for the content and writing of the paper.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Girotra, P., Singh, S.K. A Comparative Study of Orally Delivered PBCA and ApoE Coupled BSA Nanoparticles for Brain Targeting of Sumatriptan Succinate in Therapeutic Management of Migraine. Pharm Res 33, 1682–1695 (2016). https://doi.org/10.1007/s11095-016-1910-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-016-1910-8